Resistance training may curb lean mass loss with tirzepatide
MDSpire News
November 20, 2026
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

In the 40-week T-REx trial, 120 adults aged 50 to 70 years with obesity or overweight and a weight-related comorbidity received tirzepatide alone or with supervised resistance training.
Total lean soft tissue loss was 1.09 kg lower with resistance training than with tirzepatide alone, and appendicular lean soft tissue loss was 0.63 kg lower.
Resistance training improved bench press, lat pulldown, and knee extension strength, whereas strength declined in the tirzepatide-only group.
Weight, fat mass, BMI, waist circumference, and cardiometabolic changes were similar between groups.
The single-center trial used DXA to measure lean soft tissue, enrolled initially sedentary adults without diabetes or cardiovascular disease, and did not assess long-term outcomes.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise: